Spots Global Cancer Trial Database for A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
Official Title: A Phase 1-2 Dose-escalation and Expansion Study of ST316 in Subjects With Selected Advanced Unresectable and Metastatic Solid Tumors
Study ID: NCT05848739
Conditions
Interventions
Study Description
Brief Summary: This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV in subjects with selected advanced solid tumors likely to harbor abnormalities of the WNT/β-catenin signaling pathway. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Sarah Cannon Research Institute - CO, Denver, Colorado, United States
START Midwest, Grand Rapids, Michigan, United States
Duke Universtiy, Durham, North Carolina, United States
Sanford Cancer Center, Sioux Falls, South Dakota, United States
Contact Details
Name: Abi Vainstein-Haras
Affiliation: CMO
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
